# Evaluation of Circulating Tumor Cells (CTC) Relevance in Breast Cancer Follow-up Using the ScreenCell Device

> **NCT06807502** · NA · RECRUITING · sponsor: **ScreenCell** · enrollment: 93 (estimated)

## Conditions studied

- Breast Cancer, Metastatic
- Breast Cancer Invasive
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)

## Interventions

- **DEVICE:** The DM/DIV ScreenCell is the experimental product studied during this research

## Key facts

- **NCT ID:** NCT06807502
- **Lead sponsor:** ScreenCell
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-24
- **Primary completion:** 2026-09-30
- **Final completion:** 2026-11-30
- **Target enrollment:** 93 (ESTIMATED)
- **Last updated:** 2026-04-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06807502

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06807502, "Evaluation of Circulating Tumor Cells (CTC) Relevance in Breast Cancer Follow-up Using the ScreenCell Device". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06807502. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*